କୋପାନଲିସିବ

କୋପାନଲିସିବ
Clinical data
Pronunciation	Aliqopa /ˌælɪˈkoʊpə/ AL-ih-KOH-pah
Trade names	Aliqopa
Synonyms	BAY 80-6946
AHFS/Drugs.com	monograph
MedlinePlus	a617044
data	EU EMA: yes; US DailyMed: copanlisib;
Routes of; administration	intravenous infusion only
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	84.2%
Metabolism	CYP3A4/5 (≈90%), CYP1A1 (≈10%)
Elimination half-life	39.1 hours (range: 14.6 to 82.4)
Excretion	Feces (64%), Urine (22%); 14% were not recovered
Identifiers
	IUPAC name 2-Amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide;
Chemical and physical data
Formula	C23H28N8O4
Molar mass	୪୮୦.୫୩ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=CC2=C1N=C(N3C2=NCC3)NC(=O)C4=CN=C(N=C4)N)OCCCN5CCOCC5;
	InChI InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32); Key:PZBCKZWLPGJMAO-UHFFFAOYSA-N;

କୋପାନଲିସିବ, ଅଲିକୋପା ଏହାର ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଫୋଲିକୁଲାର ଲିମ୍ଫୋମା ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଯେଉଁମାନେ ଅନ୍ୟ ଚିକିତ୍ସାରେ ବିଫଳ ହୋଇଛନ୍ତି ସେମାନଙ୍କ ପାଇଁ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉଚ୍ଚ ରକ୍ତ ଶର୍କରା, ତରଳ ଝାଡ଼ା, ଦୁର୍ବଳତା, ଉଚ୍ଚ ରକ୍ତଚାପ, ସ୍ୱଳ୍ପ ଶ୍ୱାତ ରକ୍ତ କଣିକା, ଅଇ, ନିମୋନିଆ ଏବଂ ସ୍ୱଳ୍ପ ରକ୍ତ ପ୍ଲାଟେଲେଟ୍ ହୋଇପାରେ ।^[୨] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ ଏବଂ ନିମୋନାଇଟିସ୍ ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୨] ଏହା ଏକ ପିଆଇ୩-କାଇନେଜ ଇନହିବିଟର (PI3-kinase

inhibitor) ।^[୩]

୨୦୧୭ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ କୋପାନଲିସିବ୍ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୨] ୨୦୨୨ ସୁଦ୍ଧା ଏହା ବ୍ରିଟେନ କିମ୍ବା ୟୁରୋପରେ ଅନୁମୋଦିତ ହୋଇନାହିଁ ।^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ସୁଦ୍ଧା ଏହାର ଏକ ମାତ୍ରାର ମୂଲ୍ୟ ପ୍ରାୟ ୫୦୦୦ ଡଲାର ଥିଲା ।^[୫]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "FDA Prescribing information for Aliqopa" (PDF). Archived (PDF) from the original on 2021-04-06. Retrieved 2021-05-25.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ "DailyMed - ALIQOPA- copanlisib injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 18 March 2021. Retrieved 7 January 2022.
↑ "Copanlisib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 7 January 2022.
↑ "Copanlisib". SPS - Specialist Pharmacy Service. 30 December 2015. Archived from the original on 3 October 2021. Retrieved 7 January 2022.
↑ "Aliqopa Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 2019-04-12. Retrieved 2022-01-07.

[AliPI-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "FDA Prescribing information for Aliqopa" (PDF). Archived (PDF) from the original on 2021-04-06. Retrieved 2021-05-25.

[PI2022-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ ^୨.୫ ^୨.୬ "DailyMed - ALIQOPA- copanlisib injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 18 March 2021. Retrieved 7 January 2022.

[AHFS2022-3] "Copanlisib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 7 January 2022.

[SP2022-4] "Copanlisib". SPS - Specialist Pharmacy Service. 30 December 2015. Archived from the original on 3 October 2021. Retrieved 7 January 2022.

[5] "Aliqopa Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 2019-04-12. Retrieved 2022-01-07.

[୨]

[୧]

[୩]

[୪]

[୫]

Clinical data

Pronunciation	Aliqopa /ˌælɪˈkoʊpə/ AL-ih-KOH-pah
Trade names	Aliqopa
Synonyms	BAY 80-6946
AHFS/Drugs.com	monograph
MedlinePlus	a617044
data	EU EMA: yes US DailyMed: copanlisib
Routes of administration	intravenous infusion only
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	84.2%^[୧]
Metabolism	CYP3A4/5 (≈90%), CYP1A1 (≈10%)^[୧]
Elimination half-life	39.1 hours (range: 14.6 to 82.4)^[୧]
Excretion	Feces (64%), Urine (22%); 14% were not recovered^[୧]
Identifiers
IUPAC name 2-Amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide
Chemical and physical data
Formula	C₂₃H₂₈N₈O₄
Molar mass	୪୮୦.୫୩ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COC1=C(C=CC2=C1N=C(N3C2=NCC3)NC(=O)C4=CN=C(N=C4)N)OCCCN5CCOCC5
InChI InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32) Key:PZBCKZWLPGJMAO-UHFFFAOYSA-N